Key regions: Australia, Germany, United Kingdom, United States, France
The demand for immunosuppressants in Saudi Arabia has been increasing steadily in recent years, driven by various factors such as an aging population, rising prevalence of chronic diseases, and an increase in organ transplant surgeries.
Customer preferences: Patients with chronic diseases such as autoimmune disorders, inflammatory bowel disease, and rheumatoid arthritis are the primary consumers of immunosuppressants in Saudi Arabia. These patients require long-term treatment, making them loyal customers to pharmaceutical companies that provide effective and affordable medications. Additionally, due to the high costs of these medications, many patients rely on government-sponsored health insurance programs to cover the costs of their treatment.
Trends in the market: The Saudi Arabian government has been investing heavily in healthcare infrastructure, including expanding the number of hospitals and clinics, and increasing the number of medical professionals. This has led to an increase in the number of organ transplant surgeries, further driving demand for immunosuppressants. In addition, the government has been promoting the use of generic drugs, which has led to increased competition in the market and lower prices for consumers.
Local special circumstances: One unique aspect of the Saudi Arabian market is the high proportion of expatriates living in the country. These individuals often have different healthcare needs and preferences compared to Saudi nationals, which can impact the types of immunosuppressants that are in demand. Additionally, the country has a large Muslim population, which may have religious considerations when it comes to the use of certain medications.
Underlying macroeconomic factors: The Saudi Arabian economy is heavily reliant on the oil industry, which has faced significant challenges in recent years due to fluctuating oil prices and a decrease in global demand. This has led to government austerity measures, including cuts to healthcare spending. However, despite these challenges, the immunosuppressants market has remained resilient, driven by the growing demand for these medications among the population.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
